@article{vanOorschotRadesLordick2013,
  author    = {van Oorschot, Birgitt and Rades, Dirk and Lordick, Florian},
  title     = {Connections Are Clearly More Complex},
  series = {Deutsches {\"A}rzteblatt international},
  volume    = {110},
  journal   = {Deutsches {\"A}rzteblatt international},
  number    = {44},
  doi       = {10.3238/arztebl.2013.0753a},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-128837},
  pages     = {753},
  year      = {2013},
  abstract  = {No abstract available.},
  language  = {en}
}
@article{KuonBlasiUnsoeldetal.2022,
  author    = {Kuon, Jonas and Blasi, Miriam and Uns{\"o}ld, Laura and Vogt, Jeannette and Mehnert, Anja and Alt-Epping, Bernd and Oorschot, Birgitt van and Sistermanns, Jochen and Ahlborn, Miriam and Ritterbusch, Ulrike and Stevens, Susanne and Kahl, Christoph and Ruellan, Anne and Matthias, Kathrin and Kubin, Thomas and Stahlhut, Kerstin and Heider, Andrea and Lordick, Florian and Thomas, Michael},
  title     = {Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study},
  series = {Supportive Care in Cancer},
  volume    = {30},
  journal   = {Supportive Care in Cancer},
  number    = {4},
  organization    = {Arbeitsgemeinschaft Palliativmedizin (APM) of the German Cancer Society (DKG)},
  issn      = {0941-4355},
  doi       = {10.1007/s00520-021-06736-2},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-308211},
  pages     = {3131-3140},
  year      = {2022},
  abstract  = {Purpose The purpose of this study is to investigate changes over time in quality of life (QoL) in incurable lung cancer patients and the impact of determinants like molecular alterations (MA). Methods In a prospective, longitudinal, multicentric study, we assessed QoL, symptom burden, psychological distress, unmet needs, and prognostic understanding of patients diagnosed with incurable lung cancer at the time of the diagnosis (T0) and after 3 (T1), 6 (T2) and 12 months (T3) using validated questionnaires like FACT-L, National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT), PHQ-4, SCNS-SF-34, and SEIQoL. Results Two hundred seventeen patients were enrolled, 22 (10\%) with reported MA. QoL scores improved over time, with a significant trend for DT, PHQ-4, and SCNS-SF-34. Significant determinants for stable or improving scores over time were survival > 6 months, performance status at the time of diagnosis, and presence of MA. Patients with MA showed better QoL scores (FACT-L at T1 104.4 vs 86.3; at T2 107.5 vs 90.0; at T3 100.9 vs 92.8) and lower psychological distress (NCCN DT at T1 3.3 vs 5; at T2 2.7 vs 4.5; at T3 3.7 vs 4.5; PHQ-4 at T1 2.3 vs 4.1; at T2 1.7 vs 3.6; at T3 2.2 vs 3.6), but also a worsening of the scores at 1 year and a higher percentage of inaccurate prognostic understanding (27 vs 17\%) compared to patients without MA. Conclusion Patients with tumors harboring MA are at risk of QoL deterioration during the course of the disease. Physicians should adapt their communication strategies in order to maintain or improve QoL.},
  language  = {en}
}
@article{KnoedlerKoerferKunzmannetal.2018,
  author    = {Kn{\"o}dler, Maren and K{\"o}rfer, Justus and Kunzmann, Volker and Trojan, J{\"o}rg and Daum, Severin and Schenk, Michael and Kullmann, Frank and Schroll, Sebastian and Behringer, Dirk and Stahl, Michael and Al-Batran, Salah-Eddin and Hacker, Ulrich and Ibach, Stefan and Lindhofer, Horst and Lordick, Florian},
  title     = {Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer},
  series = {British Journal of Cancer},
  volume    = {119},
  journal   = {British Journal of Cancer},
  doi       = {10.1038/s41416-018-0150-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-325938},
  pages     = {296-302},
  year      = {2018},
  abstract  = {Background Peritoneal carcinomatosis (PC) represents an unfavourable prognostic factor for patients with gastric cancer (GC). Intraperitoneal treatment with the bispecific and trifunctional antibody catumaxomab (EpCAM, CD3), in addition to systemic chemotherapy, could improve elimination of PC. Methods This prospective, randomised, phase II study investigated the efficacy of catumaxomab followed by chemotherapy (arm A, 5-fluorouracil, leucovorin, oxaliplatin, docetaxel, FLOT) or FLOT alone (arm B) in patients with GC and PC. Primary endpoint was the rate of macroscopic complete remission (mCR) of PC at the time of second diagnostic laparoscopy/laparotomy prior to optional surgery. Results Median follow-up was 52 months. Out of 35 patients screened, 15 were allocated to arm A and 16 to arm B. mCR rate was 27\% in arm A and 19\% in arm B (p = 0.69). Severe side effects associated with catumaxomab were nausea, infection, abdominal pain, and elevated liver enzymes. Median progression-free (6.7 vs. 5.4 months, p = 0.71) and overall survival (13.2 vs. 13.0 months, p = 0.97) were not significantly different in both treatment arms. Conclusions Addition of catumaxomab to systemic chemotherapy was feasible and tolerable in advanced GC. Although the primary endpoint could not be demonstrated, results are promising for future investigations integrating intraperitoneal immunotherapy into a multimodal treatment strategy.},
  language  = {en}
}